Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells

Benjamin Kroger, Roni Tamari, Carmelo Gurnari, Julio Alvarenga Thiebaud, Alejandro Marinos Velarde, Yazan F Madanat, Robert H. Collins, Clayton Jackson, Vivian Irizarry Gatell, Valeria Visconte, Jaroslaw Maciejewski, David Sallman, Stephen Chung

Blood (2024) 144 (Supplement 1): 777.

https://doi.org/10.1182/blood-2024-212380

Published: 2024

Journal Articles

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Blood (2024) 144 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2024-211261

Published: 2024

Journal Articles

Bi-Allelic DDX41 Mutations Exert Stage Specific Effects on Hematopoiesis to Promote Disease

Benjamin Kroger, Yuanyuan Ji, Toby Thomas, Yazan F Madanat, Robert H. Collins, Valeria Visconte, Carmelo Gurnari, Jaroslaw Maciejewski, Stephen Chung

Blood (2024) 144 (Supplement 1): 347.

https://doi.org/10.1182/blood-2024-209425

Published: 2024

Journal Articles

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Blood (2024) 144 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2024-202596

Published: 2024

Journal Articles

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Blood (2024) 144 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2024-211178

Published: 2024

Journal Articles

Should “Medically Fit” Older Patients with Acute Myeloid Leukemia (AML) Continue to Receive Intensive Chemotherapy in the Venetoclax (VEN) Era?

Nilesh Kapoor, Ang Gao, Ruth Ikpefan, Chul Ahn, Julia Anderson, F Neslihan Kalkan, Weina Chen, Sharon Germans, Alejandro Marinos Velarde, Vivian Irrizary Gatell, Julio Alvarenga Thiebaud, Clayton Jackson, Olga K. Weinberg, Miguel Cantu, Robert H. Collins, Stephen Chung, Yazan F Madanat

Blood (2024) 144 (Supplement 1): 4234.

https://doi.org/10.1182/blood-2024-204314

Published: 2024

Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Blood (2023) 142 (Supplement 1): 5933.

https://doi.org/10.1182/blood-2023-179609

Published: 2023

Journal Articles

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Tanooha Veeramachaneni, Xingzhe Li, Neil Desai, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Robert H. Collins, Robert Timmerman, Praveen Ramakrishnan Geethakumari, Kiran Achut Kumar

Blood (2023) 142 (Supplement 1): 6283.

https://doi.org/10.1182/blood-2023-191089

Published: 2023

Journal Articles

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 6921.

https://doi.org/10.1182/blood-2023-186596

Published: 2023

Journal Articles

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Sharlene Dong, Heather Reves, Yu-Lun Liu, Radhika Kainthla, Aimaz Afrough, Julio Alvarenga, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Adeel Khan, Kiran Achut Kumar, Yazan F. Madanat, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari

Blood (2023) 142 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2023-188033

Published: 2023

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2023-181886

Published: 2023

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Benjamin Kroger, Yi Huang, Prapti Patel, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Jr., Farrukh T. Awan, Praveen Ramakrishnan, Kunal Verma, Russell Vittrup, Robert H. Collins, Madhuri Vusirikala, Yazan F. Madanat, Roni Tamari, Stephen S. Chung

Blood (2022) 140 (Supplement 1): 9833–9835.

https://doi.org/10.1182/blood-2022-171179

Published: 2022

Journal Articles

Prevalence of Clonal Hematopoiesis in Patients with Monoclonal Gammopathy of Undetermined Significance

Vianey Quaney, Benjamin Kroger, Aishwarya Sannareddy, Umar Khan, Fatma Kalkan, Robert H. Collins, Yazan F. Madanat, Madhuri Vusirikala, Yi Huang, Farrukh T. Awan, Praveen Ramakrishnan, Aimaz Afrough, Larry D. Anderson, Jr., Stephen S. Chung, Gurbakhash Kaur

Blood (2022) 140 (Supplement 1): 11418–11419.

https://doi.org/10.1182/blood-2022-171212

Published: 2022

Journal Articles

Impact of First-Line Consolidative Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL): A 'Real-World' Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Heather Reves, Fatima Mahmood, Tanushree Prasad, Akshat M Patel, Aimaz Afrough, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Praveen Ramakrishnan

Blood (2022) 140 (Supplement 1): 13184–13185.

https://doi.org/10.1182/blood-2022-170764

Published: 2022

Journal Articles

Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience

Aishwarya Sannareddy, Heather Reves, Kefyalew Jaleta, Ramyakumari .Ramiahsankarasubramanian, Hetalkumari Patel, Madhusudhanan Narasimhan, Larry D. Anderson, Jr., Aimaz Afrough, Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Alagarraju Muthukumar, Praveen Ramakrishnan Geethakumari

Blood (2022) 140 (Supplement 1): 5203–5205.

https://doi.org/10.1182/blood-2022-171001

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?

Meredith Jackson, Heather Reves, Tanushree Prasad, Akshat M Patel, Aimaz Afrough, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari

Blood (2022) 140 (Supplement 1): 5188–5189.

https://doi.org/10.1182/blood-2022-170517

Published: 2022

Journal Articles

Impact of Bridging Therapy on Infectious Complications Post CAR T-Cell Therapy: The UT Southwestern Experience

Akshat M Patel, Brian Lue, Heather Reves, Aimaz Afrough, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Jeffrey M. Tessier, Praveen Ramakrishnan Geethakumari

Blood (2022) 140 (Supplement 1): 12793–12795.

https://doi.org/10.1182/blood-2022-158778

Published: 2022

Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2022) 140 (Supplement 1): 6200–6203.

https://doi.org/10.1182/blood-2022-167316

Published: 2022

NARROW

Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Bi-Allelic DDX41 Mutations Exert Stage Specific Effects on Hematopoiesis to Promote Disease

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Should “Medically Fit” Older Patients with Acute Myeloid Leukemia (AML) Continue to Receive Intensive Chemotherapy in the Venetoclax (VEN) Era?

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Prevalence of Clonal Hematopoiesis in Patients with Monoclonal Gammopathy of Undetermined Significance

Impact of First-Line Consolidative Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL): A 'Real-World' Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience

Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?

Impact of Bridging Therapy on Infectious Complications Post CAR T-Cell Therapy: The UT Southwestern Experience

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only